Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

ABSTRACT:

Background

The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.

Methods

We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy.

Results

In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular dis

SUBMITTER: Holman RR 

PROVIDER: S-EPMC9792409 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature